Lu Zhenkai, Feng Wenye, Wang Yaxing, Zhang Xuming, Wei Xu, Chen Ming, Wang Shangquan, Cheng Ting, Cui Xin, Xie Yanming
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Front Med (Lausanne). 2025 Jun 4;12:1582533. doi: 10.3389/fmed.2025.1582533. eCollection 2025.
Postmenopausal osteoporosis (PMOP) and knee osteoarthritis (KOA) are common musculoskeletal disorders that share risk factors such as aging, hormonal changes, and inflammation. PMOP often remains asymptomatic until fractures occur, while KOA leads to pain and disability. Their comorbidity remains underexplored, particularly in community settings. This study aims to investigate the prevalence, risk factors, and clinical features of PMOP-KOA comorbidity among Beijing residents aged 45-80 years, providing evidence-based recommendations for early identification, prevention, and management.
Over 2 years, this study will conduct a PMOP-KOA screening and prospective follow-up in the Beijing community to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA. This study will undertake bone mineral density detection, collect biological samples, and record information via questionnaires.
The study aims to investigate the incidence, risk factors, and clinical characteristics of PMOP-KOA comorbidity and explore related traditional Chinese medicine syndromes based on large community-based samples in Beijing. Data on PMOP-KOA occurrence and associated risk factors over the 2 years follow-up will be available on the Chinese Clinical Trial Registry (ChiCTR2300073575).
绝经后骨质疏松症(PMOP)和膝关节骨关节炎(KOA)是常见的肌肉骨骼疾病,它们具有共同的风险因素,如衰老、激素变化和炎症。PMOP在骨折发生前通常没有症状,而KOA会导致疼痛和残疾。它们的合并症尚未得到充分研究,尤其是在社区环境中。本研究旨在调查45-80岁北京居民中PMOP-KOA合并症的患病率、风险因素和临床特征,为早期识别、预防和管理提供循证建议。
本研究将在两年内对北京社区进行PMOP-KOA筛查和前瞻性随访,以调查PMOP-KOA的发病率、风险因素和临床特征。本研究将进行骨密度检测,收集生物样本,并通过问卷调查记录信息。
本研究旨在基于北京大型社区样本,调查PMOP-KOA合并症的发病率、风险因素和临床特征,并探索相关的中医证候。两年随访期间PMOP-KOA发生情况及相关风险因素的数据将在中国临床试验注册中心(ChiCTR2300073575)上公布。